Navigation Links
Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis

es in RRMS. The most common side effects of COPAXONE(R) are redness, pain, swelling, itching, a lump or an indentation at the site of injection, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness.

COPAXONE(R) is now approved in 47 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In Europe, COPAXONE(R) is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. In North America, COPAXONE(R) is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA). COPAXONE(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

See additional important information at http://www.copaxone.com/pi/index.html or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Incorporated,(Nasdaq: VICL ) today announced the receipt ... from AnGes MG, Inc., under a previously announced,collaborative ... Phase 3 metastatic melanoma trial. Through a series ... $15.3 million to date,of the $22.6 million total ...
... vaccine induced neutralizing antibodies against widely divergent ... Baxter International,Inc. (NYSE: BAX ) announced publication ... England Journal of Medicine (NEJM) of data demonstrating ... I/II trial,endpoints for safety and immunogenicity (generating a ...
Cached Medicine Technology:Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 2Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 3Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 2The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 3The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 5
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
... RANCHO CORDOVA, Calif., March 9 ... program announced it helped the 500,000th child since ... almost $100 million in free eyecare and eyewear ... http://www.newscom.com/cgi-bin/prnh/20090309/SF80394 )Sight for Students started as ...
... Usage Trends and Growing Uninsured Population Raise Concerns ... Report from HealthLeaders-InterStudy NASHVILLE, Tenn., March 9 ... market intelligence, reports that through the first three ... health insurers saw on average a 25 percent ...
... with therapy if subjects are willing and motivatedANN ARBOR, Mich., ... raised in an upper-middle class suburb, she felt a deep ... basement where she rode her Big Wheel at age 3 ... 8.As years went by, the home,s empty spaces disappeared, replaced ...
... Nu Skin Presents Findings at Asian Societies of Cosmetic ... a newly identified internal free radical generator, age-related NOX ... (NYSE: NUS ) links the enzyme to ... The research was presented at the 9th Scientific Conference ...
... Philanthropist and Renowned Chef Art Smith Creates Oat-Inspired Menu ... In Times Square today, Quaker announces ... purpose movement powered by Quaker and the human energy ... lives every day with the wholesome goodness of whole-grain ...
... wireless customer relationship management (CRM) experts, today ... and compliance software solution. iComply helps companies ... email for improved compliance with government regulations, ... The software is offered with a Lotus ...
Cached Medicine News:Health News:VSP's Sight for Students Program Helps 500,000th Child 2Health News:VSP's Sight for Students Program Helps 500,000th Child 3Health News:Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry 2Health News:Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry 3Health News:Compulsive Hoarding Poses Safety and Psychological Risks 2Health News:Compulsive Hoarding Poses Safety and Psychological Risks 3Health News:Study Links Internal Source of Aging and Skin Damage 2Health News:Study Links Internal Source of Aging and Skin Damage 3Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 2Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 3Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 4Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 5Health News:iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software 2Health News:iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software 3
... Peg electrodes typically are positioned ... enable epidural recording of brain ... and are furnished in several ... thicknesses. A 4.6 mm twist ...
... cortical strip electrodes are extra thin ... through a burr hole. The narrow ... enables quick and secure attachment to ... Integra Epilepsy electrode designs, they are ...
... John R. Gates and Mary E. Dunn ... are designed for reliability, safety and ease ... electrodes, platinum contacts are mounted flush with ... have larger exposures. Strip and depth electrodes ...
Integra Epilepsy grid electrodes are thin and flexible for easier placement and to conform to the curvature of the cortical surface. Lead tunneling is done using a 14-gauge tunneling needle (ET-2)....
Medicine Products: